Position in GUTS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$15,856
+$6,710 QoQ
Shares Held
19,971
0.0% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#54
of 76 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Verition Fund Management LLC holds $152,220,097 across 64 Biotechnology names. GUTS ranks #60 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
438,746 | $30,997,404 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
159,256 | $21,138,048 | |
| 3 | ABVX |
Abivax S.A.
|
105,791 | $14,097,708 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
184,054 | $6,859,692 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
304,939 | $6,665,966 | |
| 6 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
777,738 | $4,853,085 | |
| 7 | CYTK |
Cytokinetics Inc
|
54,889 | $4,675,993 | |
| 8 | RPRX |
Royalty Pharma plc
|
75,000 | $4,205,250 |
All Filings in GUTS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,856 | 19,971 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,146 | 19,971 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $120,802 | 54,910 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||